Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AR | P10275 | 3/20 | 0.57 |
| ▸ | CDK9 | P50750 | 14/20 | 0.54 |
| ▸ | CCNT1 | O60563 | 13/20 | 0.54 |
| ▸ | MAP4K4 | O95819 | 2/20 | 0.49 |
| ▸ | CDK1 | P06493 | 2/20 | 0.49 |
| ▸ | CDK4 | P11802 | 2/20 | 0.49 |
| ▸ | CCNB1 | P14635 | 2/20 | 0.49 |
| ▸ | CCND1 | P24385 | 2/20 | 0.49 |
| ▸ | ABL2 | P42684 | 2/20 | 0.49 |
| ▸ | GSK3A | P49840 | 2/20 | 0.49 |
| ▸ | CDK7 | P50613 | 2/20 | 0.49 |
| ▸ | CCNH | P51946 | 2/20 | 0.49 |
| ▸ | MNAT1 | P51948 | 2/20 | 0.49 |
| ▸ | CCNA2 | P20248 | 1/20 | 0.49 |
| ▸ | CDK2 | P24941 | 1/20 | 0.49 |
| ▸ | CCNA1 | P78396 | 1/20 | 0.49 |
| ▸ | CDK5 | Q00535 | 1/20 | 0.49 |
| ▸ | CDK5R1 | Q15078 | 1/20 | 0.49 |
| ▸ | USP2 | O75604 | 1/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4098710 | 0.88 | CDK9 (0.64) | CDK9CCNT1MAP4K4CDK1CDK4 | |
| SCHEMBL17022949 | 0.86 | CDK9 (0.63) | ARCDK9CCNT1MAP4K4CDK1 | |
| SCHEMBL4666199 | 0.85 | AR (0.69) | ARMEN1GAAKMT2A | |
| SCHEMBL4101912 | 0.83 | CDK9 (0.67) | CDK9CCNT1MAP4K4CDK1CDK4 | |
| SCHEMBL4104620 | 0.82 | USP2 (0.68) | CDK9CCNT1MAP4K4CDK1CDK4 | |
| SCHEMBL4108268 | 0.82 | CCNT1 (0.67) | CDK9CCNT1MAP4K4CDK1CDK4 | |
| SCHEMBL4665854 | 0.81 | BACE1 (0.60) | USP2ALDH1A1LMNACYP1A2CYP2D6 | |
| SCHEMBL4098113 | 0.81 | USP2 (0.63) | CDK9CCNT1MAP4K4CDK1CDK4 | |
| SCHEMBL4667473 | 0.81 | MEN1 (0.51) | CDK9CCNT1MAP4K4CDK1CDK4 | |
| SCHEMBL4109219 | 0.80 | CDK9 (0.77) | CDK9CCNT1MAP4K4CDK1CDK4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080242681-A1 | N-4-(6-(Hetero)Aryl-Pyrimidin-4-Ylaminophenyl)-Benzenesulfonamides as Kinase Inhibitors | ALTANA PHARMA AG (DE) | 2008-10-02 | — | — | US | claimed |
| EP-1709007-A1 | N-4-(6-(HETEO)ARYL-PYRIMIDIN-4-YLAMINOPHENYL)-BENZENESULFONAMIDES AS KINASE INHIBITORS | Altana Pharma AG (DE) | 2006-10-11 | — | — | EP | claimed |
| WO-2005070900-A1 | N-4-(6- (HETEO) ARYL-PYRIMIDIN-4-YLAMINOPHENYL) -BEZENESULFONAMIDES AS KINASE INHIBITORS | ALTANA PHARMA AG (DE) | 2005-08-04 | — | — | WO | claimed |
| US-20080242681-A1 | N-4-(6-(Hetero)Aryl-Pyrimidin-4-Ylaminophenyl)-Benzenesulfonamides as Kinase Inhibitors | ALTANA PHARMA AG (DE) | 2008-10-02 | — | — | US | disclosed |
| EP-1709007-A1 | N-4-(6-(HETEO)ARYL-PYRIMIDIN-4-YLAMINOPHENYL)-BENZENESULFONAMIDES AS KINASE INHIBITORS | Altana Pharma AG (DE) | 2006-10-11 | — | — | EP | disclosed |
| WO-2005070900-A1 | N-4-(6- (HETEO) ARYL-PYRIMIDIN-4-YLAMINOPHENYL) -BEZENESULFONAMIDES AS KINASE INHIBITORS | ALTANA PHARMA AG (DE) | 2005-08-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080242681-A1 | N-4-(6-(Hetero)Aryl-Pyrimidin-4-Ylaminophenyl)-Benzenesulfonamides as Kinase Inhibitors | MAP3K19, MAP3K6, MAP3K20 | AR 1425/4885CDK9 49/4885CCNT1 217/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.